<DOC>
	<DOCNO>NCT01643967</DOCNO>
	<brief_summary>This open , phase III , multicenter , prospective , comparative , control , randomize clinical trial evaluate efficacy safety use ozone release Philozon Medplus device versus conventional therapy treat patient diabetic foot .</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety Use Ozone Versus Sunflower Oil Treating Diabetic Foot</brief_title>
	<detailed_description>- Clinical trial , open , phase III , multicenter , prospective , comparative , control , randomize evaluate efficacy safety use ozone release Philozon Medplus device versus conventional therapy treat patient diabetic foot . - Primary Objective : evaluate efficacy safety ozone release device Philozon Medplus treatment patient diabetic foot . - Secondary objective : evaluate ozone analyzer environmental ozone Philozon Medplus release device clinical set use device rectal insufflation patient diabetic foot . - Study population : Patients sex , consist 100 patient 18 year , patient diabetic foot . - Treatment : 50 patient receive ozone therapy ( topical rectal insufflation ozone ) . 50 patient receive conventional treatment ( Sunflower Oil ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<criteria>Consent form sign ; Patients Diabetes Mellitus Type I Type II trophic lesion present low limb ; Injury whose large diameter le 5 cm ; Patients sex , age 18 year ; Heart rate 60 100 bpm . Presence severe septic condition ; IMC &gt; 30 ; Presence Lymphedema ; Presence trophic lesion low limb : exudative , traumatic parasitic ; Trophic lesion cause venous disease require treatment ; Hepatic renal dysfunction ; History alcohol abuse drug last 6 month ; Laboratory parameter : hemoglobin &lt; 10 g/dl ; Glycated hemoglobin &gt; 9 % ; Diagnosis hyperthyroidism ( TSH &lt; 0.50 Î¼UI/mL , free T4 &gt; 1.80 ng/dL ) ; Deficit Glucose 6 Phosphate Dehydrogenase ( G6PD ) &gt; 20 % ; Use immunosuppressive drug anticonvulsant ; Pregnant woman lactate ; Any significant medical condition opinion Investigator may bring risk patient ; Known hypersensitivity drug and/or treatment use study ; Inability compliance protocol ; Participation another clinical trial le 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Ozone</keyword>
	<keyword>Sunflower oil</keyword>
	<keyword>diabetes Mellitus</keyword>
</DOC>